ALS: Clinical Trials

13 trials for ALS, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed. 13 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 213Completed 13
Phase 12Completed 2

Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)
IFB-088 50mg/day, Placebo, Riluzole 100mg/day - Amyotrophic Lateral Sclerosis, ALS
Phase 2CompletedInFlectis BioScience512022-12-022025-10-10
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
PrimeC, Placebo - Amyotrophic Lateral Sclerosis, ALS
Phase 2CompletedNeuroSense Therapeutics Ltd.692022-05-312025-09-05
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
LAM-002A, Placebo - Amyotrophic Lateral Sclerosis, ALS
Phase 2CompletedIRulya Therapeutics Inc.152021-12-232026-09-29
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS
Fixed dose combination Ciprofloxacin/Celecoxib - Amyotrophic Lateral Sclerosis, ALS
Phase 2CompletedNeuroSense Therapeutics Ltd.162019-11-252021-03-03
A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
Triheptanoin - ALS
Phase 1 / Phase 2CompletedRichard Bedlack, M.D., Ph.D.152018-06-212019-12-24
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
Ranolazine 500 MG, Ranolazine 1000 MG - ALS
Phase 2CompletedUniversity of Kansas Medical Center142018-06-112024-12-09
Open Label Extension Study of AMX0035 in Patients With ALS
AMX0035 - Amyotrophic Lateral Sclerosis, ALS
Phase 2CompletedAmylyx Pharmaceuticals Inc.902018-03-292025-08-13
Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)
Perampanel, placebo - ALS
Phase 2CompletedTokyo Medical University662017-04-242021-01-15
Effect of MD1003 in Amyotrophic Lateral Sclerosis
MD1003, Placebo oral capsule - ALS, Amyotrophic Lateral Sclerosis
Phase 2CompletedMedDay Pharmaceuticals SA302016-06-292019-06-04
A Trial of Tocilizumab in ALS Subjects
Tocilizumab, Placebo - ALS, Amyotrophic Lateral Sclerosis
Phase 2CompletedBarrow Neurological Institute222015-11-012019-12-18
Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
HYNR-CS inj, Control group - Amyotrophic Lateral Sclerosis, ALS
Phase 1 / Phase 2CompletedCorestemchemon, Inc.722011-02-012022-03-17
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
Talampanel, placebo - ALS
Phase 2CompletedTeva Branded Pharmaceutical Products R&D, Inc.5592008-09-012011-10-21
Phase II Study Using Thalidomide for the Treatment of ALS
Thalidomide - Amyotrophic Lateral Sclerosis, ALS
Phase 2CompletedDartmouth-Hitchcock Medical Center242005-02-012007-11-21

Narrower conditions

Amyotrophic Lateral Sclerosis (9)  ·  Motor Neuron Disease (4)  ·  Frontotemporal Dementia With Motor Neuron Disease (1)  ·  Neurodegenerative Diseases (1)

Broader conditions

Central Nervous System Diseases (9)  ·  Metabolic Diseases (9)  ·  Nervous System Diseases (9)  ·  Neuromuscular Diseases (9)  ·  Nutritional and Metabolic Diseases (9)  ·  Proteostasis Deficiencies (9)  ·  Spinal Cord Diseases (9)  ·  TDP-43 Proteinopathies (9)  ·  Neurodegenerative Diseases (8)  ·  Motor Neuron Disease (5)

Interventions

4-phenylbutyric acid (1)  ·  Biotin (1)  ·  Celecoxib (1)  ·  Control Groups (1)  ·  Ranolazine (1)  ·  Riluzole (1)  ·  Sodium Chloride (1)  ·  Thalidomide (1)  ·  perampanel (1)  ·  sodium phenylbutyrate and taurursodiol (1)  ·  talampanel (1)  ·  tocilizumab (1)  ·  triheptanoin (1)  ·  ursodoxicoltaurine (1)

Sponsors

NeuroSense Therapeutics Ltd. (2)  ·  Amylyx Pharmaceuticals Inc. (1)  ·  Barrow Neurological Institute (1)  ·  Corestemchemon, Inc. (1)  ·  Dartmouth-Hitchcock Medical Center (1)  ·  IRulya Therapeutics Inc. (1)  ·  InFlectis BioScience (1)  ·  MedDay Pharmaceuticals SA (1)  ·  Richard Bedlack, M.D., Ph.D. (1)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (1)  ·  Tokyo Medical University (1)  ·  University of Kansas Medical Center (1)

Countries

United States (7)  ·  France (3)  ·  Israel (3)  ·  Italy (3)  ·  Canada (2)  ·  Belgium (1)  ·  Germany (1)  ·  Hungary (1)  ·  Japan (1)  ·  Netherlands (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Elijah Stommel (1)  ·  Giuseppe Lauria, Pr (1)  ·  Jeffrey Statland, MD (1)  ·  Richard S Bedlack, MD PhD (1)  ·  Sabrina Paganoni, MD, PhD (1)  ·  Seung Hyun Kim, M.D., Ph.D. (1)  ·  Shafeeq Ladha, MD (1)  ·  Shahram Attarian, Pr (1)  ·  Suma Babu, M.D. (1)  ·  Tomohiro Haga (1)  ·  Vivian Drory, MD (1)

Results publications

PMID 25934946, PMID 30048006, PMID 32140672, PMID 33063909, PMID 34075589, PMID 35508892, PMID 35577511, PMID 38606777, PMID 41837970